Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 22 , ISSUE 3 ( 2018 ) > List of Articles

EDITORIAL

Comparison of Glycemic Control Between Continuous Regular Insulin Infusion and Single-Dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients

Rungsun Bhurayanontachai, Tharittamon Rattanaprapat, Chanon Kongkamol

Keywords : Blood glucose, critically ill patients, glycemic control, insulin glargine, regular insulin

Citation Information : Bhurayanontachai R, Rattanaprapat T, Kongkamol C. Comparison of Glycemic Control Between Continuous Regular Insulin Infusion and Single-Dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients. Indian J Crit Care Med 2018; 22 (3):174-179.

DOI: 10.4103/ijccm.IJCCM_273_17

License: CC BY-ND 3.0

Published Online: 01-05-2018

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Background and Aims: This study aimed to compare glycemic control between continuous intravenous regular insulin infusion and single-dose subcutaneous insulin glargine injection in medical critically ill patients. Subjects and Methods: A prospective noninferiority study was conducted in medical critically ill patients who developed hyperglycemia and required regular insulin infusion by the Intensive Care Unit glycemic control protocol. The eligible patients were switched from the daily regular insulin requirement to single-dose subcutaneous insulin glargine injection by a 100% conversion dose. Arterial blood glucose was checked every 2 h for 24 h. Success cases were blood glucose levels of 80–200 mg/dL during the study period. The mean time-averaged area under the curves (AUCs) of blood glucose levels between the two types of insulin were compared by t-test. Results: Of 20 cases, 14 cases (70%) were successful. The mean time-averaged AUCs of blood glucose levels between the two types of insulin were not significantly different (155.91 ± 27.54 mg/dL vs. 151.70 ± 17.07 mg/dL, P = 0.56) and less than the predefined noninferior margin. No severe hypoglycemic cases were detected during the study period. Conclusions: Single-dose subcutaneous insulin glargine injection was feasibly applied for glycemic control in medical critically ill patients. The glycemic control in the critically ill patients by a single dose of subcutaneous insulin glargine was comparable to standard intravenous regular insulin infusion. A conversion dose of 100% of the daily requirement of regular insulin is suggested.

PDF Share
  1. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003;78:1471-8.
  2. Bosarge PL, Shoultz TH, Griffin RL, Kerby JD. Stress-induced hyperglycemia is associated with higher mortality in severe traumatic brain injury. J Trauma Acute Care Surg 2015;79:289-94.
  3. Kerby JD, Griffin RL, MacLennan P, Rue LW 3rd. Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma. Ann Surg 2012;256:446-52.
  4. Khan SA, Ibrahim MN, Anwar-ul-Haq. Frequency and mortality associated with hyperglycemia in critically ill children. J Coll Physicians Surg Pak 2015;25:878-81.
  5. Krinsley JS. Moving closer to untangling a sweet web: Hyperglycemia, diabetic status, and mortality in the critically ill. Crit Care Med 2010;38:295-6.
  6. Douketis J. Review: Stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetes. ACP J Club 2002;136:114.
  7. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
  8. Cavalcanti AB, Silva E, Pereira AJ, Caldeira-Filho M, Almeida FP, Westphal GA, et al. Arandomized controlled trial comparing a computer-assisted insulin infusion protocol with a strict and a conventional protocol for glucose control in critically ill patients. J Crit Care 2009;24:371-8.
  9. Nichols R, Zawada E, Johnson T, Aaronson ML, Herr P, Casanova J, et al. Implementation of an insulin protocol using a multiplier-based calculation for determining infusion rates in critically ill patients. S D Med 2008;61:247, 249-53.
  10. Dickerson RN, Swiggart CE, Morgan LM, Maish GO 3rd, Croce MA, Minard G, et al. Safety and efficacy of a graduated intravenous insulin infusion protocol in critically ill trauma patients receiving specialized nutritional support. Nutrition 2008;24:536-45.
  11. Roth JM, Bolin B, Baird RW. Evaluation of blood glucose values in critically ill patients before and after implementation of an intensive insulin infusion protocol. Proc (Bayl Univ Med Cent) 2007;20:237-9.
  12. Orford N, Stow P, Green D, Corke C. Safety and feasibility of an insulin adjustment protocol to maintain blood glucose concentrations within a narrow range in critically ill patients in an australian level III adult intensive care unit. Crit Care Resusc 2004;6:92-8.
  13. Campbell RK, White JR, Levien T, Baker D. Insulin glargine. Clin Ther 2001;23:1938-57.
  14. McKeage K, Goa KL. Insulin glargine: A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-624.
  15. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001;24:2005-6.
  16. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001;18:619-25.
  17. Bhurayanontachai R, Kongkamol P, Kongkamol C. A pilot study of a comparison of glycemic control in critically ill patients with a single dose subcutaneous injection of glargine versus continuous intravenous infusion of regular insulin. Songkla Med J 2010;28:237-45.
  18. Krinsley JS. Glycemic control in the critically ill: What have we learned since NICE-SUGAR? Hosp Pract (1995) 2015;43:191-7.
  19. Todi S. Glycemic control in critically ill: A moving target. Indian J Crit Care Med 2014;18:229-33.
  20. Krinsley JS. Should guidelines for glycemic control of the critically ill be individualized?: Weighing the evidence from randomized and observational investigations. Hosp Pract (1995) 2014;42:14-22.
  21. Hsu CW. Glycemic control in critically ill patients. World J Crit Care Med 2012;1:31-9.
  22. Ashwell SG, Home PD. Insulin glargine: The first clinically useful extended-action insulin analogue. Expert Opin Pharmacother 2001;2:1891-902.
  23. Rosenstock J, Schwartz SL, Clark CM Jr., Park GD, Donley DW, Edwards MB, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
  24. Schmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, et al. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract 2006;12:641-50.
  25. Datta S, Qaadir A, Villanueva G, Baldwin D. Once-daily insulin glargine versus 6-hour sliding scale regular insulin for control of hyperglycemia after a bariatric surgical procedure: A randomized clinical trial. Endocr Pract 2007;13:225-31.
  26. Silinskie KM, Kirshner R, Hite MS. Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: A pilot trial. Ann Pharmacother 2013;47:20-8.
  27. Todi S, Bhattacharya M. Glycemic variability and outcome in critically ill. Indian J Crit Care Med 2014;18:285-90.
  28. Krinsley JS. Glycemic variability and mortality in critically ill patients: The impact of diabetes. J Diabetes Sci Technol 2009;3:1292-301.
  29. Krinsley JS. Glycemic variability: A strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36:3008-13.
  30. Brunner R, Adelsmayr G, Herkner H, Madl C, Holzinger U. Glycemic variability and glucose complexity in critically ill patients: A retrospective analysis of continuous glucose monitoring data. Crit Care 2012;16:R175.
  31. Haas CE, Forrest A. Pharmacokinetic and pharmacodynamic research in the Intensive Care Unit: An unmet need. Crit Care Med 2006;34:1831-3.
  32. Doshi P, Potter AJ, De Los Santos D, Banuelos R, Darger BF, Chathampally Y, et al. Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: A pilot study. Acad Emerg Med 2015;22:657-62.
  33. Yeldandi RR, Lurie A, Baldwin D. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery. Diabetes Technol Ther 2006;8:609-16.
  34. Finfer S, Wernerman J, Preiser JC, Cass T, Desaive T, Hovorka R, et al. Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults. Crit Care 2013;17:229.
  35. Bhurayanontachai R. Agreement of blood glucose levels between venous blood test and arterial blood glucometer in the ICU. Neth J Crit Care 2016;24:11-5.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.